Victory Capital Management Inc. Makes New Investment in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Key Points

• Victory Capital Management Inc. has acquired a new position in Kiniksa Pharmaceuticals, purchasing 53,317 shares valued at approximately $1.18 million, representing 0.07% of the company.
• Wall Street analysts are optimistic about Kiniksa Pharmaceuticals, with price targets increasing; Wells Fargo raised its target from $30 to $42 and Jefferies from $45 to $54, reflecting a consensus "Buy" rating.
• Insider transactions indicate significant activity, with CEO Sanj K. Patel selling 62,116 shares worth about $1.7 million, reducing his ownership in the company by 39.12%.

Victory Capital Management Inc. acquired a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 53,317 shares of the company's stock, valued at approximately $1,184,000. Victory Capital Management Inc. owned 0.07% of Kiniksa Pharmaceuticals International as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new position in Kiniksa Pharmaceuticals International during the 1st quarter valued at about $301,000. GAMMA Investing LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the last quarter. Nuveen Asset Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 7.3% in the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after purchasing an additional 54,361 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Kiniksa Pharmaceuticals International by 46.3% in the 4th quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock worth $1,381,000 after purchasing an additional 22,096 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 28.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 56,691 shares of the company's stock worth $1,121,000 after purchasing an additional 12,462 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, insider Ross Moat sold 27,594 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total transaction of $800,777.88. Following the transaction, the insider directly owned 9,415 shares in the company, valued at approximately $273,223.30. The trade was a 74.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barry D. Quart sold 12,336 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $30.39, for a total transaction of $374,891.04. Following the transaction, the director directly owned 12,546 shares of the company's stock, valued at approximately $381,272.94. This trade represents a 49.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 320,981 shares of company stock valued at $9,189,467 over the last ninety days. 53.48% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA traded up $1.72 during mid-day trading on Friday, hitting $31.98. The company's stock had a trading volume of 1,072,119 shares, compared to its average volume of 611,693. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of 799.70 and a beta of 0.14. The company's fifty day simple moving average is $28.38 and its 200-day simple moving average is $24.10. Kiniksa Pharmaceuticals International, plc has a one year low of $17.82 and a one year high of $32.15.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Saturday. Wells Fargo & Company raised their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Finally, Jefferies Financial Group raised their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of "Buy" and an average target price of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.